Country: Malta
Language: English
Source: Medicines Authority
VORICONAZOLE
Medochemie Limited 1-10 Constantinoupleos Street, 3011 Limassol, Cyprus
J02AC03
VORICONAZOLE 200 mg
FILM-COATED TABLET
VORICONAZOLE 200 mg
POM
ANTIMYCOTICS FOR SYSTEMIC USE
Authorised
2017-01-11
1 PACKAGE LEAFLET: INFORMATION FOR THE USER VERRIA 50 MG FILM-COATED TABLETS VERRIA 200 MG FILM-COATED TABLETS Voriconazole READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. . Keep this leaflet. You may need to read it again. . If you have any further questions, ask your doctor, pharmacist or nurse. . This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. . If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : 1. What Verria is and what it is used for 2. What you need to know before you take Verria 3. How to take Verria 4. Possible side effects 5. How to store Verria 6. Content of the pack and other information 1. WHAT VERRIA IS AND WHAT IT IS USED FOR Verria contains the active substance voriconazole. Verria is an antifungal medicine. It works by killing or stopping the growth of the fungi that cause infections. It is used for the treatment of patients (adults and children over the age of 2) with: • invasive aspergillosis (a type of fungal infection due to _Aspergillus sp_ ), • candidaemia (another type of fungal infection due to _Candida sp_ ) in non-neutropenic patients(patients without abnormally low white blood cells count), • serious invasive _Candida sp. _ infections when the fungus is resistant to fluconazole (another antifungal medicine), • serious fungal infections caused by _Scedosporium sp. _ or _Fusarium sp_ . (two different species of fungi). Verria is intended for patients with worsening, possibly life-threatening, fungal infections. Prevention of fungal infections in high risk bone marrow transplant recipients. This product should only be taken under the supervision of a doctor. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE VERRIA DO NOT TAKE VERRIA: If you are allergic to voriconazole or any of the other Read the complete document
SPCvorictabs-1.7MT SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Verria 50 mg film-coated tablets Verria 200 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION [For 50 mg strength:] Each tablet contains 50 mg voriconazole. Excipient with known effect: lactose monohydrate 67.8 mg. [For 200 mg strength:] Each tablet contains 200 mg voriconazole. Excipient with known effect: lactose monohydrate 271.2 mg. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM [For 50 mg strength:] White to off-white, round film-coated tablets of approximately 7.2 mm in diameter. [For 200 mg strength:] White to off-white, capsule-shaped film-coated tablets of approximately 15.9 x 8.0 mm. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: Treatment of invasive aspergillosis. Treatment of candidaemia in non-neutropenic patients. Treatment of fluconazole-resistant serious invasive _Candida_ infections (including _C. krusei_ ). Treatment of serious fungal infections caused by _Scedosporium_ spp. and _Fusarium_ spp. Verria should be administered primarily to patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. SPCvorictabs-1.7MT 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.4). Verria is also available as 200 mg/ [50 mg] film-coated tablets. Treatment _Adults_ Therapy must be initiated with the specified loading dose regimen of either intravenous or oral voriconazole to achieve plasma concentrations on Day 1 that are close to steady state. On the basis of the high oral bioavailability (96%; see section 5.2), switching betw Read the complete document